Full Phase III results unveiled for CSL's first-in-class antibody

27 February 2023
cslbig

Detailed Phase III results for a new long-term prophylactic treatment for hereditary angioedema (HAE) have been presented at the annual meeting of the American Academy of Allergy Asthma & Immunology (AAAAI).

Developed by Australian biotech company CSL Limited (ASX: CSL), garadacimab is an investigational first-in-class treatment which uniquely inhibits the plasma protein, FXIIa.

CSL, which hopes to offer the once-monthly subcutaneous treatment for attacks related to HAE,  announced top-line results from the VANGUARD study in August 2022.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology